https://www.selleckchem.com/pr....oducts/BMS-790052.ht
These studies thus suggest that BP may serve as novel delivery strategy for lung cancer. Eculizumab, the first anti-C5 monoclonal antibody approved for patients with paroxysmal nocturnal hemoglobinuria (PNH), has revolutionized the natural history of this disease, blocking intravascular hemolysis, reducing the risk of thromboembolic events, resulting in a significant improvement in survival and quality of life. However, the hematological response to eculizumab is extremely heterogeneous, with only one-third of PNH patients reaching n
Curtir
Comentario
Compartilhar
